| Clinical characteristic | Triple Antibiotic (n = 346) | Irrisept (n = 344) | p |
| Age, mean years | 49.7 | 52.1 | 0.007 |
| BMI, mean kg/m2 | 25.3 | 25.6 | 0.402 |
| Smoking history, n (%) | 11 (3.2) | 16 (4.7) | 0.334 |
| Diabetes mellitus, n (%) | 23 (6.6) | 21 (6.1) | 0.876 |
| Hypertension, n (%) | 78 (22.5) | 115 (33.4) | 0.002 |
| Mastectomy type, n (%) |
|
| <0.0001 |
| Modified radical | 2 (0.6) | 5 (1.5) |
|
| Skin-sparing | 288 (83.7) | 194 (56.4) |
|
| Nipple-sparing | 54 (15.7) | 145 (42.2) |
|
| Laterality, n (%) |
|
| 0.258 |
| Unilateral | 96 (27.9) | 82 (23.8) |
|
| Bilateral | 248 (72.1) | 262 (76.2) |
|
| Lymph node dissection, n (%) |
|
|
|
| Sentinel lymph node biopsy | 269 (78.2) | 269 (78.2) | 1.000 |
| Axillary lymph node dissection | 100 (29.1) | 78 (22.7) | 0.067 |
| Chemotherapy, n (%) |
|
|
|
| Any | 164 (47.4) | 115 (33.4) | <0.0001 |
| Neoadjuvant | 82 (23.7) | 79 (23.0) | 0.857 |
| Adjuvant | 98 (28.3) | 55 (16.0) | <0.0001 |
| Radiotherapy, n (%) |
|
|
|
| Any | 99 (28.6) | 69 (20.1) | 0.010 |
| Neoadjuvant | 4 (1.2) | 15 (4.4) | 0.013 |
| Adjuvant | 98 (28.3) | 56 (16.3) | <0.0001 |
| Primary Reconstruction, n (%) |
|
| <0.0001 |
| Tissue expander | 317 (91.6) | 220 (64.0) |
|
| Direct-to-implant | 29 (8.4) | 93 (27.0) |
|
| Latissimus flap/expander | 0 (0.0) | 31 (9.0) |
|
| Use of acellular dermal matrix | 194 (56.6) | 174 (50.6) | 1.000 |
| Complications, n (%) |
|
|
|
| Any complication | 110 (31.8) | 77 (22.4) | 0.006 |
| Ipsilateral (to cancer side) | 81 (23.4) | 59 (17.2) | 0.047 |
| Contralateral (to cancer side) | 32 (9.2) | 19 (5.5) | 0.080 |
| Major complication | 69 (19.9) | 55 (16.0) | 0.198 |
| Minor complication | 57 (16.5) | 30 (8.7) | 0.003 |
| Delayed wound healing | 1 (0.3) | 10 (2.9) | 0.006 |